In this issue: Key themes of CPHI 2026, the GLP-1 manufacturing shift, cold chain logistics, and more.
Unlike other therapies in this class, Abogen’s ABO2203 is designed to produce a T-cell engager protein in vivo through an mRNA-encoded system.
The agreement will see Sanofi and Regeneron co-develop and co-commercialise four long-lasting antibodies.
Tirzepatide delivers stronger real-world glycaemic and weight-loss outcomes than oral and injectable semaglutide in type 2 diabetes.
Varda secures this capital as drugmakers tout the potential of manufacturing in microgravity conditions to create differentiated medicines.
Nordic biopharma innovation outpaces commercialisation as regional biotechs struggle to raise the capital needed to upscale.
